Comprehensive coverage

Compiogen: proof of biological activity of therapeutic molecules discovered with the help of his calculation methods

The molecules are candidates for the treatment of several types of cancer, inflammatory diseases and cardiovascular diseases

Hayadan

Compugen reported today the proof of biological activity of molecules with medicinal (therapeutic) activity that it discovered with the help of computational methods. These therapeutic candidates were discovered with the help of a computational search engine unique to the company. The molecules may be used as drugs to treat a variety of cancers, inflammatory diseases and cardiovascular diseases.

The search engine that predicted the existence of the molecules is the first of the company's therapeutic search engines, which was designed to identify new variants (splice variants of proteins with medicinal indications. The search engine predicts the protein products of the human genome according to a model unique to the company. After Prediction and initial biological characterization, the company had twelve candidates that showed biological activity in cell cultures. Of these, five with high priority were selected and these underwent a wider biological characterization, both in cell cultures and in animals. Based on these results, three have now been selected for further development.

"We are satisfied with this further proof of the ability of Compuage's search engines, and that we successfully met the goal of selecting and characterizing the first group of therapeutic candidates before the end of 2006," said Dr. Noam Shani, Compuage's VP of Therapeutics N. "Based on the positive results we have, the company has begun discussions with various companies regarding the granting of licenses for use or possible collaborations." The molecules selected for further development are CGEN-241, CGEN-54 and CGEN-34:

CGEN-241 is a new variant of the c-Met receptor. This receptor activates a pathway involved in a wide variety of biological processes, including cell proliferation and survival, cell migration, and blood vessel formation. Defective activation of this pathway is involved in the development of various cancerous tumors. CGEN-241 is a protein that is only part of the complete receptor and is therefore expected to inhibit the activity of the c-Met receptor. Indeed, in the experiments conducted, CGEN-241 showed a significant ability to inhibit several biological processes activated by c-MET. These experiments suggest that CGEN-241 has the potential to be used as an anti-cancer drug.

CGEN-54 is a new version of the MCP1 protein that is expressed in the body in response to various inflammatory events and causes the immune system cells to migrate to the sites of inflammation. In chronic inflammatory conditions, the activity of MCP1 often causes the destruction of the tissue in which it operates. Experiments conducted in cell cultures and animals showed that CGEN-54 is able to inhibit the migration of cells in culture. A similar inhibitory activity was also demonstrated in the treatment of peritonitis in mice. CGEN-54 may help prevent the deterioration process of chronic inflammatory diseases such as multiple sclerosis.

CGEN-34 is a new version of the ANP hormone. This hormone causes the drop in blood pressure and the excretion of water and salts by the kidney. ANP and a similar protein from the same hormone family are already being used medicinally to treat heart failure. The biological activity of CGEN-34 has been demonstrated in both cell cultures and animals. CGEN-34 showed activation of the ANP receptor in cell cultures as well as a variety of physiological activities in rats, such as lowering blood pressure and heart rate, and increasing urine volume and salt concentration.

Leave a Reply

Email will not be published. Required fields are marked *

This site uses Akismat to prevent spam messages. Click here to learn how your response data is processed.